ERBB2 and breast carcinoma: HER2-positive (HER2+) breast tumors are more aggressive and historically have been associated with poorer outcomes compared to HER2-negative (HER2-) tumors, although the introduction of HER2-targeted therapies has allowed for significant improvements in survival of patients with HER2+ breast cancer [3–5].